RxDoctor Payments Data

Colin Burnett, MD

Cardiovascular Disease · Milwaukee, WINPI 1205284197

Payments from drug & device makers

What this record shows

This record is dominated by grants: $15,000 of the $24,928 with a category attached, or 60.2%. Medtronic accounts for 94.2% of it on its own, with 8 other manufacturers making up the rest. Among cardiovascular disease clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,928in general payments, 2019–2025

Across 104 payments — averaging $239.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$23K
  • Abbott$554
  • Boston Scientific$234
  • Biotronik Inc.$226
  • Biosense Webster, Inc.$153
  • Getinge USA Sales, LLC$107
  • plus $164 from 3 others

What the payments were for

  • Grants$15,00060%
  • Travel & lodging$4,93820%
  • Food & beverage$4,44118%
  • Education$5492%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,928 in reported general payments places this provider in the 90th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$31,648
Medicare patients
236
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$40,337
Metoprolol Succinate36$471
Mupirocin15$121

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →